Скачать или смотреть ILYX-002 Achieves Endpoints in Phase 2 Trial, With Penny Asbell, MD, MBA

ILYX-002, an investigative topical immunomodulator from Iolyx Therapeutics, has proven its efficacy in treating dry eye disease by achieving its primary endpoint of total conjunctivial staining in a recent phase 2 trial. We sat down with Penny Asbell, MD, MBA, clinical professor of ophthalmology at UTHSC and external professor of biomedical engineering at the University of Memphis, to discuss the implications of this trial and the potential advancements it represents in a difficult-to-diagnose, difficult-to-manage disease.

"One of the nice things that we saw in this trial is corneal staining, which had a significant improvement that seems clinically significant," Asbell told HCPLive. "We want something that’s rapid, and we want something that really works, and that’s what we saw in this very first trial. So it’s not as big as some of the future trials we’ll do, but we already saw very significant results.”

00:00 Introduction
00:05 Overview of the trial
01:11 Explaining the recovery speed without steroid risks
02:05 Interpreting the massive reduction in corneal staining
02:57 Comparing subjective improvements in quality of life
04:21 Differences between subgroups
06:01 How will ILYX-002 fit into the treatment landscape?
07:13 Could ILYX-002 have a broader impact beyond DED?
08:03 Final thoughts

Read the full article here: https://www.hcplive.com/view/ilyx-002...

#DED #ophthalmology